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ABSTRACT
Background
Pancreatic b-cell ATP-sensitive potassium (KATP) channels are critical links between nutrient
metabolism and insulin secretion. In humans, reduced or absent b-cell KATP channel activity
resulting from loss-of-function KATP mutations induces insulin hypersecretion. Mice with
reduced KATP channel activity also demonstrate hyperinsulinism, but mice with complete loss of
KATP channels (KATP knockout mice) show an unexpected insulin undersecretory phenotype.
Therefore we have proposed an ‘‘inverse U’’ hypothesis to explain the response to enhanced
excitability, in which excessive hyperexcitability drives b-cells to insulin secretory failure
without cell death. Many patients with type 2 diabetes treated with antidiabetic sulfonylureas
(which inhibit KATP activity and thereby enhance insulin secretion) show long-term insulin
secretory failure, which we further suggest might reflect a similar progression.
Methods and Findings
To test the above hypotheses, and to mechanistically investigate the consequences of
prolonged hyperexcitability in vivo, we used a novel approach of implanting mice with slow-
release sulfonylurea (glibenclamide) pellets, to chronically inhibit b-cell KATP channels.
Glibenclamide-implanted wild-type mice became progressively and consistently diabetic, with
significantly (p , 0.05) reduced insulin secretion in response to glucose. After 1 wk of
treatment, these mice were as glucose intolerant as adult KATP knockout mice, and reduction of
secretory capacity in freshly isolated islets from implanted animals was as significant (p , 0.05)
as those from KATP knockout animals. However, secretory capacity was fully restored in islets
from sulfonylurea-treated mice within hours of drug washout and in vivo within 1 mo after
glibenclamide treatment was terminated. Pancreatic immunostaining showed normal islet size
and a-/b-cell distribution within the islet, and TUNEL staining showed no evidence of apoptosis.
Conclusions
These results demonstrate that chronic glibenclamide treatment in vivo causes loss of insulin
secretory capacity due to b-cell hyperexcitability, but also reveal rapid reversibility of this
secretory failure, arguing against b-cell apoptosis or other cell death induced by sulfonylureas.
These in vivo studies may help to explain why patients with type 2 diabetes can show long-
term secondary failure to secrete insulin in response to sulfonylureas, but experience
restoration of insulin secretion after a drug resting period, without permanent damage to b-
cells. This finding suggests that novel treatment regimens may succeed in prolonging
pharmacological therapies in susceptible individuals.
The Editors’ Summary of this article follows the references.
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Pancreatic b-cell ATP-sensitive potassium (KATP) channels
are a critical link between nutrient metabolism and insulin
secretion, maintaining the blood sugars in a narrow physio-
logical range. In fasted animals, KATP channels provide the
dominant b-cell membrane conductance, maintaining the cell
in a hyperpolarized state and stopping insulin secretion.
Conversely, in the fed state, glucose metabolism increases the
[ATP]/[ADP] ratio, closing KATP channels, causing membrane
depolarization and voltage-dependent Ca
2þ entry, which in
turn trigger insulin secretion [1].
The KATP channel is a heteroctameric complex composed
of four inwardly rectifying K
þ channel subunits (Kir6.2) and
four sulfonylurea (SU) receptors (SUR1) [2]. Loss-of-function
mutations of b-cell KATP channel subunits (SUR1, ABCC8,
OMIM accession number 600509; and Kir6.2, KCNJ11, OMIM
600937; GenBank, http://www.ncbi.nlm.nih.gov/) underlie con-
genital hyperinsulinism (HI) in humans [3–7], a genetic
disease characterized by relative hyperinsulinemia and
hypoglycemia [8]. In HI, reduced or absent KATP channel
activity is expected to result in constitutive depolarization,
elevated intracellular [Ca
2þ], and hypersecretion of insulin
[9]. In order to replicate the human disease, mice lacking
Kir6.2 or SUR1 and mice expressing dominant-negative
mutant Kir6.2-encoding transgenes have been generated.
Kir6.2- or SUR1-knockout (KO) mice show insulin hyper-
secretion immediately after birth, but rapidly and unexpect-
edly progress to glucose intolerance and insulin
hyposecretion as adults [10–12]. Conversely, the b-cell–
speciﬁc Kir6.2[AAA] dominant-negative mouse [13] demon-
strates only a ;70% decrease in b-cell KATP channel activity,
and exhibits insulin hypersecretion with hyperinsulinemia
that persist through adulthood. Heterozygous Kir6.2
þ/  and
SUR1
þ/  mice, which also have reduced KATP gene dosage
(;60%), also show enhanced glucose tolerance and glucose-
sensitive insulin secretion (GSIS) that is maintained through-
out adulthood, without progression to secretory failure [14].
We therefore conclude that varying degrees of genetic
suppression of KATP channel activity will all lead to enhanced
excitability, but with different long-term consequences for
insulin secretion, depending on the severity of suppression:
incomplete loss of KATP channels (e.g., in Kir6.2[AAA] [13] or
in heterozygous Kir6.2
þ/  or SUR1
þ/  mice [14]) causes a
maintained hyperinsulinism, whereas complete loss (in
Kir6.2- and SUR1-KO mice) causes transient hypersecretion
that is followed by a secretory deﬁcit and reduced glucose
tolerance [10–12]. The recombinant phenotypes of many HI
mutations [6,15,16] actually suggest that reduced, but not
complete, absence of KATP channels [17] is likely. Henwood et
al. [18] have demonstrated that some HI patients with KATP
channel mutations clearly maintain some KATP channel
activity, because the patients were responsive to KATP channel
drugs. There are also limited reports that some HI patients,
even those nonsurgically treated, can spontaneously progress
to type 2 diabetes [19–21]. HI is also often present at the onset
of clinically overt type 2 diabetes, which is interpreted as the
endocrine pancreas trying to compensate for primary defects
in insulin sensitivity in the peripheral tissues [22]. Thus the
progression from relative to absolute insulin deﬁciency by
decreasing insulin secretory capacity appears as the result of
a detrimental long-term increased workload of b-cells [23].
SUs, such as tolbutamide and glibenclamide (glyburide), are
widely used in patients with type 2 diabetes, because they
induce insulin secretion independently of the metabolic state
of the b-cell [24–26]. These antidiabetic drugs bind to the
SUR1 subunit, leading to inhibition of KATP channel activity,
membrane depolarization, and insulin secretion. Patients with
type 2 diabetes chronically treated with SUs often progress to
a failure of b-cells to secrete insulin [27–29]. The systemic or
cellular mechanism underlying such failure is not well
understood, although itcould be linked eitherto the evolution
of the disease or to a speciﬁc effect of the drugs [30–32].
Consistent with all these studies, the UK Prospective Diabetes
Study (UKPDS) revealed that 48% of the patients with type 2
diabetes treated for 6 y with glibenclamide required addi-
tional therapy to maintain their normal blood sugars [33].
Despite the widespread use of SUs, there is also evidence
that chronic SU (tolbutamide and glibenclamide) treatment
may induce Ca
2þ-dependent b-cell apoptosis in rat islets [34]
and human islets incubated with glibenclamide demonstrated
a signiﬁcant decrease in insulin content (24 h incubation), as
well as an approximate 2-fold increase in b-cell apoptosis (4 d
incubation) [35,36]. Glibenclamide-treated Min6 cells report-
edly also showed a reversible reduction in insulin content and
an accelerated apoptotic b-cell death [37–39], although SU
(glibenclamide)-induced apoptosis was apparently speciﬁcally
enhanced only by expression of the receptor SUR1, but not
SUR2B, in HEK 293 cells [40].
The parallels between the long-term consequence of
genetic hyperexcitability in mice and desensitization/apopto-
sis to prolonged SU treatment in humans lead us to
hypothesize that, in vivo, SUs will induce an increase in
electrical activity leading to enhanced insulin secretion in the
short term, but that in the longer term they may still cause
membrane hyperexcitability but paradoxically lead to insulin
secretory failure, reproducing the KATP channel KO mouse
phenotype. In this paper we speciﬁcally tested this hypothesis
using a novel pharmacological approach by implanting slow-
release (90 d) SU (glibenclamide) pellets.
Methods
Animals
Wild-type C57BL/6 mice were obtained from Jackson
Laboratories (6-wk-old males, JAX mice; http://jaxmice.jax.
org/). Kir6.2 KO mice (a gift from Dr. Susumo Seino) were
originally generated by targeted disruption of the gene
encoding Kir6.2 in the 129Sv mouse strain [10]. SUR1 KO
mice (a gift from Dr. Mark Magnuson) were originally
generated in the C57BL/6 mice by pronuclear microinjection
of 1 ng/ll CMV-Cre expression vector (pBS185) into embryos
obtained from a mating of Sur1
loxþneo/w and Sur1
w/w mice [11].
All experiments were performed in compliance with the
relevant laws and institutional guidelines, and were approved
by the Washington University Animal Studies Committee.
Acute Glibenclamide Injection in Wild-Type C57BL/6 Mice
Fed wild-type (WT) mice were acutely injected with
glibenclamide (0, 1, 3, 10, and 30 lg) and tested for blood
glucose levels over time. Intraperitoneal glucose–glibencla-
mide tolerance tests were performed in fasted (12 h) 6-wk-old
WT mice by simultaneous injection of a bolus of glucose (1.5
g/kg) plus glibenclamide at the indicated doses. Glibencla-
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injection of 30 lg/ml in fed mice. Blood was assayed for
glucose content using the Glucometer Elite XL (Bayer, http://
www.bayer.com).
Blood Glucose and Plasma Insulin Measurements on Mice
Implanted with Glibenclamide Pellets
Glibenclamide (glyburide) pellets at the concentration of
0.0001, 0.001, 0.025, 0.25, and 2.5 mg per 90-d release were
obtained from Innovative Research of America (Sarasota, FL).
Six-week old males were anesthetized with tribromoethanol
(Avertin; 0.25 mg/g mouse body weight). The skin on the
lateral side of the neck of the animal was lifted and pellets
were implanted under the skin of the neck using a stainless
steel precision trochar. Blood samples taken from the tail
vein in fed and fasting conditions, and during glucose
tolerance tests (GTTs), were assayed for glucose content as
described above. Intraperitoneal GTTs were performed in
WT, Kir6.2-KO, and SUR1-KO mice implanted with different
glibenclamide pellet concentrations. For insulin tolerance
tests (ITTs), mice were injected with 0.5 U insulin/kg following
6-h fasting. Blood was taken at different times (as indicated in
ﬁgures) and assayed for glucose content. Plasma insulin was
measured on glibenclamide-treated mice at 2 d and 42 d after
pellet implantation using a rat insulin ELISA kit.
Islet Isolation
Mice were anesthetized with halothane (0.2 ml) in an
anesthetizing chamber and killed by cervical dislocation.
Pancreata were removed and injected with Hank’s balanced
salt solution (HBSS; Sigma-Aldrich, http://www.sigmaaldrich.
com/) containing collagenase (0.3 mg/ml) (pH 7.4). Collage-
nase type XI was obtained from Sigma-Aldrich. Pancreata
were digested for 5 min at 37 8C, hand-shaken, and washed
three times in cold HBSS solution [41]. Islets were isolated by
hand under a dissecting microscope and pooled islets were
maintained in CMRL-1066 culture medium (GIBCO) supple-
mented with fetal calf serum (FCS, 10%), penicillin (100 units/
ml), and streptomycin (100 lg/ml).
86Rb
þ Efflux Experiments
Isolated islets were pre-incubated with
86Rb
þ (rubidium
chloride 1.5 mCi/ml, Amersham Biosciences) for 1 h. Loaded
islets were placed in microcentrifuge tubes (30 per group) and
washed twice with RPMI-1640 media (Sigma-Aldrich).
86Rb
þ
efﬂux was assayed by replacing the bathing solution with
Ringer’s solution with metabolic inhibitor (MI), with or
without 1 lmol/l glibenclamide. MI solution contained 2.5
mg/ml oligomycin, 1 mM 2-deoxyglucose, together with 10 mM
tetraethylammonium to block voltage-gated K
þ channels, 10
lM nifedipine to block Ca
2þentry, and 30 mM KCl to maintain
Em ; 0. The bathing solution was replaced with fresh solution
every5minovera40minperiod,andcountedinascintillation
counter.
86Rb efﬂux was ﬁtted by a single exponential and the
reciprocal of the exponential time constant (rate constant) for
each efﬂux experiment is then proportional to the K
þ (Rb
þ)
conductance of the islet membranes.
Insulin Release Experiments
Acutely, following isolation, or after overnight incubation
in low-glucose (5.6 mM) CMRL-1066, islets (ten per well in 12-
well plates) were preincubated for 30 min in glucose-free
CMRL-1066 plus 3 mM D(þ)-glucose, then incubated in
CMRL-1066 plus different glucose concentration, as indi-
cated. Islets were incubated for 60 min at 37 8C and medium
removed and assayed for insulin content. Isolated islets were
sonicated on ice prior to estimation of insulin content.
Insulin was measured using rat insulin radioimmunoassay
according to manufacturer’s procedure (Linco, http://www.
millipore.com). Experiments were repeated in triplicate.
Immunohistological Analysis
Pancreata from WT, Kir6.2 KO, and SUR1 KO mice treated
for 56 d with placebo or glibenclamide pellets were ﬁxed in
10% formalin and parafﬁn embedded for serial sectioning (5
lm thick). Hematoxylin-eosin (HE) staining was carried out as
described previously [42]. For insulin and glucagon immuno-
ﬂuorescence, pancreatic sections were incubated overnight at
37 8C with a guinea pig anti-insulin primary antibody or a
guinea pig anti-glucagon primary antibody (1:250 or 1:500,
respectively; Linco). Primary antibodies were detected by
incubating for 1.5 h at 25 8C with an anti-guinea pig
secondary antibody conjugated with the Alexa 488 ﬂuores-
cent dye (Molecular Probes, http://www.invitrogen.com) [42].
Apoptosis was assessed on parafﬁn sections using the TUNEL
staining technique (ApopTag Plus Fluorescein In Situ
Apoptosis Detection Kit, Chemicon International, httpp://
www.millipore.com). DNAase I recombinant (Roche) was used
to damage DNA as a positive control for the experiment.
Statistics
Data are presented as mean 6 standard error of the mean
(SEM). Differences between the non-implanted control group
and the pellet-implanted groups were assessed using analysis
of variance (ANOVA) within each time point. When
signiﬁcant and within the framework of the ANOVA, the
Duncan post hoc test was used to test speciﬁc hypotheses
about the equivalence of the control group with each test
group. When only two groups were compared, unpaired t-
tests were used to assess signiﬁcance. Differences were
assumed to be signiﬁcant in each case if p , 0.05. When the
sample size was three or less, statistics were not performed
and signiﬁcance is not assigned. Given sample size limitations,
we did not use a multilevel model to compare change over
time between groups. Unless stated otherwise, asterisks in
ﬁgures indicate signiﬁcant difference between the test group
and the control group within time point or condition, non-
signiﬁcant differences are not indicated.
Results
Glucose Tolerance Is Enhanced and Fed Glucose Is
Reduced in WT Mice Acutely Injected with Glibenclamide
Six-week-old C57BL/6 WT mice simultaneously injected with
1.5g/kgglucoseandglibenclamide(0,1,3,10,and30lg)showed
a dose-dependent enhancement of glucose tolerance, with a
more rapid glucose decline compared with control mice
injected with only glucose (Figure 1A). Consistent with the
well-known acute effect of SUs on blood sugars, and in
correlation with the glibenclamide effect on the GTT, these
acute injections caused a rapid, dose-dependent drop in blood
glucose levels. Importantly, the two highest concentrations of
glibenclamide (10 and30lg) causeda similar markedreduction
of fed blood glucose after an extended period, consistent with a
saturated effect of the drug in vivo (Figure 1B).
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Treated with Glibenclamide
As discussed in the Introduction, KATP KO mice show an
unexpected phenotype that contradicts the simple prediction
for complete inhibition of KATP channel activity [10–12]. We
have previously shown that this phenotype depends on
complete, or nearly complete loss of KATP, while intermediate
loss induces insulin hypersecretion [14]. We suggest that this
biphasic response proﬁle is a direct consequence of loss of
KATP and resultant hyperexcitability. In order to pharmaco-
logically test this hypothesis, we took advantage of the
availability of slow-release implantable drug pellets. Mice
were chronically treated with glibenclamide, a speciﬁc KATP
channel blocker, by pellet implantation at 6 wk of age. We
could thus examine long-term (90 d) effects of the drug,
avoiding the peak and valley effect produced by single
injections and the stress of frequent injections.
During the ﬁrst four days following implantation with high-
dose slow-release glibenclamide pellets, fed blood glucose
levels in WT mice were signiﬁcantly lower than in placebo-
implanted mice (Figure 1C), and the glucose-lowering effect
was glibenclamide-dose–dependent. The circulating gliben-
clamide level is unknown in these experiments. However,
therapeutic glibenclamide doses in humans are typically
around 0.05 mg/kg/d. Pellets containing 0.1 mg released over
90 d should give a similar net dose in a 25 g mouse; thus, the
implanted doses (0.0001–2.5 mg) should span therapeutic
ranges. The initial decrease in fed blood sugars was lost
within a few days, and fed blood glucose was signiﬁcantly
higher in implanted animals after 4–5 d, for all implanted
doses except the very lowest 0.0001 mg dose (Figure 1C). Two
weeks after pellet implantation, all glibenclamide-treated
mice (with the exception of those with the 0.0001 mg pellet)
showed similar elevated fed blood glucose, and this elevated
level persisted without further impairment until 42 d after
implantation (Figure 1C). The elevation was essentially the
same as that seen in placebo-treated KATP KO mice, with no
signiﬁcant differences between glibenclamide- and placebo-
treated KO mice (Figure 1C and 1D).
Impaired Glucose Tolerance in WT Mice Chronically
Treated with High Doses of Glibenclamide
As previously reported, Kir6.2 KO and SUR1 KO mice are
less glucose tolerant than WT mice [10–12], as illustrated by
intraperitoneal GTT (Figure 2A). WT mice implanted with
high-dose glibenclamide pellets (0.25 and 2.5 mg/pellet,
equivalent to a release of 3 and 30 lg/d) showed very rapid
progression to impaired glucose tolerance compared to WT
placebo-treated mice (Figure 2B–2D). After only 7 d (Figure
Figure 1. Acute and Chronic Effect of Glibenclamide on Glucose Tolerance and Blood Glucose Levels
In each graph, asterisks indicate control group is significantly different (p , 0.05) from the test group at the specified time point.
(A) GTTs on 6-wk-old WT mice (n ¼ 10) fasted for 12 h and intraperitoneally injected with 1.5 g/kg glucose and glibenclamide simultaneously.
(B) Blood glucose response of fed 6-wk-old mice (n ¼ 10) to acute injection of glibenclamide.
(C) Fed blood glucose from WT and Kir6.2 knockout (Kir6.2KO) mice implanted with placebo or glibenclamide pellets (0.0001 or 2.5 mg/pellet) over time.
(D) Individual values of fed glucose (plus mean and SEM) from WT control and glibenclamide-pelleted mice, as well as Kir6.2-KO and SUR1-KO mice
implanted with 2.5 mg pellets, at 1 and 42 d after implantation.
Each group in (C) and (D) contained ten to 15 mice.
doi:10.1371/journal.pmed.0050206.g001
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(Figure 2D), glibenclamide-treated mice were as glucose
intolerant as KO mice. Moreover, KATP KO mice chronically
treated with glibenclamide show no change in the preexisting
glucose-intolerant response. Thus, pharmacological block of
the KATP channel in WT mice essentially reiterates the loss of
glucose tolerance seen in KATP channel KO mice.
Enhanced Glucose Tolerance, but Crossover to a
Progressive Impairment of Glucose Tolerance, in Mice
Implanted with Low-Dose Glibenclamide Pellets
GTTs were also performed in mice implanted with pellets
containing much lower doses of glibenclamide (Figure 3). An
early (2 or 7 d after implantation) mild enhancement of
glucose tolerance was detectable in mice implanted with a
very low dose of glibenclamide (0.001 or 0.0001 mg/pellet,
Figure 3B and 3C, respectively), but this was again followed by
a progressive impairment in glucose tolerance over time
(Figures 3C and 3D). Again, 42 d postimplantation, 0.001 mg/
pellet–treated mice showed similar impairment in glucose
tolerance to mice treated with high doses of glibenclamide
for the same period of time (Figures 2D and 3D). However,
this crossover was markedly delayed with the very lowest dose
(0.0001 mg/pellet); at 7 d glucose tolerance was signiﬁcantly
enhanced, although at 42 d, blood glucose and glucose
tolerance were similar to control. Thus, at very low doses, the
‘‘pelleted’’ mice resemble heterozygous KATP knockout mice
[13,14,43], at least for a period of 2–7 d.
In Vivo Dose- and Time-Dependent Changes in Insulin
Secretion in Response to Glucose Injection in Mice
Chronically Treated with Glibenclamide Pellets
Two days after implantation, plasma insulin was very
slightly elevated in mice treated with 0.001 mg pellets, but was
dose-dependently reduced in all mice treated with higher
doses for the same period. At 42 d after glibenclamide
treatment, fed plasma insulin was signiﬁcantly reduced in all
implanted mice (Figure 4A), paralleling the marked increase
Figure 2. Impaired Glucose Tolerance in Mice Implanted with High Dose Slow-Release Glibenclamide Pellets
GTTsonWTmice before(A),2 d(B), 7d(C),42d(D),95d(E),and118d(F)afterimplantationofpelletscontaininghighdoses ofglibenclamide.Eachgroup
contained ten mice, except five in (E) and (F). Mice were injected intraperitoneally with glucose (1.5 g/kg). Blood was taken at times indicated and assayed
forglucoseconcentration.Ineachgraph,asterisksindicatecontrolgroupissignificantlydifferent(p,0.05)fromthetestgroupatthespecifiedtimepoint.
doi:10.1371/journal.pmed.0050206.g002
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dose. Glucose-stimulated insulin secretion (GSIS) in vivo was
assessed from plasma insulin values 30 min after glucose
challenge. Insulin secretion in response to glucose was
increased in mice treated with the lowest dose of glibencla-
mide, consistent with the enhanced glucose tolerance
observed in these mice 2 d after drug implantation. Also
consistent with changes in glucose tolerance, all other
glibenclamide-implanted mice showed a dose-dependent
reduction in insulin secretion that worsened over time
(Figure 4B).
No Effect of Acute Glibenclamide Injection, and Normal
Insulin Sensitivity in Mice Chronically Treated with
Glibenclamide
To test whether the glucose-intolerant phenotype of
chronically glibenclamide-treated mice is still correlated with
loss of function of KATP channel activity, the response to
acute injection of glibenclamide was measured at the times
indicated. As expected for complete or near complete
inhibition of the channel by the circulating drug levels,
injection of glibenclamide produced no signiﬁcant effect in
mice chronically treated with high-dose pellets, and only a
modest lowering of blood sugars in mice implanted with low-
dose pellets (Figure 4C).
To assess insulin sensitivity in peripheral tissues, WT
placebo- and glibenclamide-implanted mice were subjected
to an ITT. Mice implanted with both low and high doses of
glibenclamide showed similar insulin sensitivity to WT-
placebo-implanted mice (Figure 4D).
Glibenclamide-Treated Islets Exhibit a Marked Reduction
of KATP Conductance
Macroscopic KATP channel density in freshly isolated
(within 2 h) intact islets was assessed by
86Rb
þ efﬂux under
metabolic inhibition to lower cellular [ATP]:[ADP] and
Figure 3. Enhancement and Crossover of Glucose Tolerance in Mice Implanted with Low Dose Slow-Release Glibenclamide Pellets
In each panel, asterisks indicate control group is significantly different (p , 0.05) from the test group at the specified time point.
GTTsperformedonWT micebefore(A), 2d (B),7 d(C),42d(D), 95d(E),and118d(F)after implantationof pelletscontaininghighdosesof glibenclamide.
Groups contained ten mice each, except five in (E) and (F). Note: The lowest-dose pellets (0.0001 mg) were examined only at 14 and 42 d postimplant.
doi:10.1371/journal.pmed.0050206.g003
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efﬂux rate constant (proportional to available KATP con-
ductance) was signiﬁcantly reduced in glibenclamide-im-
planted mice compared with placebo-treated mice,
indicating reduced K
þ conductance. In WT placebo-treated
islets, over 70% of the ﬂux was glibenclamide-sensitive;
however, WT glibenclamide-treated islets showed less than
40% glibenclamide-sensitive efﬂuxes (Figure 5), indicating
that KATP conductance was substantially reduced. Consistent
with a reversible effect of the drug to inhibit the channel
directly, maintenance of isolated islets from glibenclamide-
implanted mice in the absence of the drug for 24 h (in vitro
drug washout) show a dramatic recovery of glibenclamide-
sensitive K
þ conductance, without changes in glibenclamide-
insensitive
86Rb
þ efﬂuxes (Figure 5).
The assay of freshly isolated islets was made within 2 h of
isolation, at which point there is clearly signiﬁcant inhibition
of KATP conductance in islets from implanted mice. However,
realizing that full recovery occurs within 24 h, it seems likely
that some recovery occurs even within this 2 h, so the
measured KATP activity at that time is at best an upper limit
estimate, and channel activity in vivo may have been
completely suppressed by the circulating glibenclamide
levels.
Chronically Glibenclamide-Treated Mice Show Reduced
GSIS from Fresh Isolated Islets, but Restored Normal
Insulin Secretion in Drug-Washout Islets
In order to assess the effect of long-term glibenclamide
treatment on b-cell function directly, pancreatic islets were
Figure 4. Drug and Insulin Responsivity In Vivo
In each graph, asterisks indicate control group is significantly different (p , 0.05) from the test group at the specified time point.
(A) Individual fed plasma insulin (plus mean and SEM) in glibenclamide-treated mice, 2 d and 42 d after glibenclamide implantation.
(B) Individual values (plus mean and SEM) of plasma insulin 30 min after glucose injection (normalized to control unpelleted) at either 2 d or 42 d.
(C and D) WT mice 5 wk implanted with different doses of glibenclamide were intraperitoneally injected with glibenclamide (C) or with insulin (D) and
blood glucose was assessed over time.
(E and F) Control and high-dose glibenclamide-pelleted mice were intraperitoneally injected with 20 mg/kg diazoxide, and blood glucose was assessed
over time. In (F), glucose is normalized to the precontrol value (indicated by broken line).
doi:10.1371/journal.pmed.0050206.g004
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with glibenclamide for 42 d. Insulin content of KO islets was
slightly lower than WT islets, but insulin content was not
signiﬁcantly different between placebo- and pellet-implanted
animals (Figure 6A). However, while freshly isolated islets
from WT placebo-treated mice showed robust glucose- and
glibenclamide-dependent insulin secretion, glibenclamide-
treated WT and KATP KO islets both showed a similar,
severely blunted response to both glucose and glibenclamide
(Figure 6B). A 24 h incubation in CMRL medium (5.6 mM
glucose, glibenclamide washout) restored normal glucose and
glibenclamide responses in islets obtained from WT gliben-
clamide-treated mice (Figure 6C), paralleling the recovery of
KATP conductance. However, as expected, insulin secretion
was not improved in islets from glibenclamide-treated KATP
KO mice.
Reversal of Phenotype Is also Observed In Vivo
The above results dramatically demonstrate rapid reversi-
bility in vitro of the chronic glucose-desensitizing effects of
glibenclamide. Removal of pellets to assess reversibility in
vivo is impractical, so instead we examined glucose control in
implanted mice, beyond the time at which release should
cease (95 or 118 d). In this case, the animals should have been
exposed to glibenclamide for the full 90-d release period, but
then should have had either 5 d or 28 d without drug
exposure. Partial restoration was detectable at 5 d after drug
release (Figures 2E and 3E) was terminated, and even mice
that had been implanted with 2.5 mg glibenclamide/pellet
showed dramatic restoration of both insulin secretion and
glucose tolerance 118 d after pellet implantation (i.e., 28 d
after the drug release was terminated) (Figures 2F and 3F).
The restoration of secretion following the cessation of
glibenclamide release raises the question of whether secretion
might also be acutely restored by diazoxide treatment (to
activate KATP and block the hyperexcitability) during the
period of glibenclamide release. Acutely, diazoxide may cause
glucose to rise, but in ‘‘resting’’ the b-cells may also transiently
allow recovery of insulin ‘‘releasability,’’ leading to a transient
restoration of normal glucose. We performed the experiment
on control and high-dose (2.5 mg) pelleted animals. As
predicted, there was a rise in glucose in both cases, but a
markedsubsequentprolonged undershootonly inthepelleted
animals (Figure 4E and 4F).
Morphology of Pancreas and a-/b-Cell Distribution within
Islets from Glibenclamide-Implanted Mice Is Not Altered
The normal content of insulin and rapid recovery of
secretion in isolated islets from glibenclamide-treated ani-
mals would seem to rule out apoptotic or necrotic effects of
the drug on b-cells. However, to conﬁrm this, immunohis-
tochemical analyses were performed on sectioned pancreata
from 9-wk glibenclamide-implanted mice. Hematoxylin-eosin
staining showed similar pancreatic architecture in glibencla-
mide-implanted vs. placebo-treated mice (Figure 7A, left
photomicrographs). Immunostaining for insulin and gluca-
gon conﬁrmed normal distribution of both insulin-contain-
ing b-cells and glucagon-containing a-cells, with no obvious
changes in islet size (Figure 7A, middle and right photo-
micrographs). No marked redistribution of a-/b-cells or loss
of b-cell mass (i.e., reduced insulin immunoﬂuorescence) was
observed in glibenclamide-treated mice, although there was a
very slight tendency for a-cell inﬁltration in the core of
glibenclamide-treated pancreatic islets. In order to speciﬁ-
cally test for the possibility of enhanced b-cell death, in situ
immunostaining for apoptosis was performed in parafﬁn-
ﬁxed sections using the TUNEL technique (Figure 7B).
Pancreatic sections were costained with insulin (green) and
TUNEL (red). The absence of red staining in the left images of
Figure 7B indicates no obvious b-cell apoptosis was present in
islets from control or high dose (0.25 and 2.5 mg/pellet)
glibenclamide-pelleted mice. As positive control, consecutive
pancreatic sections from each sample were treated with
recombinant DNAase I, resulting in extensive TUNEL
positivity in endocrine as well as exocrine cells (Figure 7B,
right photomicrographs).
Discussion
In the present study, we examined the ‘‘inverse U’’
hypothesis to explain the response to enhanced excitability,
in which excessive hyperexcitability drives b-cells to insulin
secretory failure [14,42], using a novel approach of implant-
ing mice with slow-release sulfonylurea (glibenclamide)
pellets, to chronically inhibit b-cell KATP channels. Gliben-
clamide-implanted wild-type mice became progressively and
consistently diabetic, with signiﬁcantly reduced insulin
secretion in response to glucose. After 1 wk of treatment,
these mice were as glucose intolerant as adult KATP knockout
mice, with similar loss of secretory capacity. However,
secretory capacity was fully restored in these islets within
hours of drug washout in vitro, or within 1 mo after
Figure 5. Glibenclamide-Treated Islets Exhibit a Reduction of Total KATP
Channel Density Macroscopic KATP channel density in intact islets from
WT placebo- and glibenclamide-treated mice was assessed by
86Rb
þ
effluxes under metabolic inhibition (MI) in the presence and absence of
glibenclamide (glib.). Fluxes were fitted by single exponentials and
reciprocal rate constant plotted in the figure (each case contained three
animals; no significance assessed). Broken line indicates KATP-independ-
ent rate constant, determined by glibenclamide in control islets.
doi:10.1371/journal.pmed.0050206.g005
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immunostaining showed normal islet size and a-/b-cell
distribution within the islet, and TUNEL staining showed
no evidence of apoptosis.
Hyperexcitability and Hyperinsulinism in Animal Models
and Humans: Key Features and Discrepancies
Glucose metabolism increases the b-cell [ATP]:[ADP] ratio,
leading to closure of KATP channels, membrane depolariza-
tion and Ca
2þ inﬂux. The resultant rise in intracellular Ca
2þ
([Ca
2þ]i) triggers insulin secretion. Reduced or absent KATP
channel activity is expected to result in constitutive mem-
brane depolarization, elevated [Ca
2þ]i, and hypersecretion of
insulin. Consistent with this prediction, loss-of-function
mutations of KATP channel subunits (SUR1, ABCC8 or
Kir6.2, KCNJ11) underlie congenital HI in humans [9].
Conversely, gain-of-function mutations of Kir6.2 or SUR1
are expected to cause an undersecreting phenotype and
hypoinsulinemia—and consistent with this prediction, acti-
vating mutations in KATP cause both permanent and transient
neonatal diabetes [44,45].
Genetic manipulation of KATP channel subunits in mice has
conﬁrmed some of the basic expectations of the above
paradigm and reiterated some features of human disease,
although conﬂicting and contradictory ﬁndings illustrate
additional complexities, particularly for models of reduced
KATP channel activity. Mice that completely lack KATP
channels do not reiterate the HI phenotype in any simple
way. In these mice, hypersecretion reportedly occurs imme-
diately after birth, but there is rapid progression to a relative
undersecretion and glucose intolerance [10–12]. There is thus
an apparent discrepancy between the outcome of genetic loss
of KATP channels in mice and humans. One important
potential caveat to consider is whether patients typically
have a complete loss of KATP channels, and therefore whether
complete KO mice are appropriate models for the disease.
Both trafﬁcking and functional mutations will probably tend
to cause only a relative loss of KATP conductance. Mice
expressing a dominant-negative Kir6.2[AAA] transgene in b-
cells, as well as mice heterozygous for Kir6.2 or SUR1, may
model such a condition, since they show substantial, but
incomplete, reduction of KATP channel activity (;60%–70%).
All of these models demonstrate both an enhanced glucose
stimulation of insulin secretion and hyperinsulinism that
persists through adulthood [13,14,43].
Biphasic Response to KATP Inhibition: Pharmacological
Verification of the ‘‘Inverse-U’’ Model for b-Cell Response
to Hyperexcitability
We therefore propose that varying degrees of genetic
suppression of KATP channels will all lead to enhanced
excitability and insulin secretion, but with potentially very
different long-term consequences depending on the severity
of suppression: incomplete loss of KATP channels (e.g., in
Kir6.2[AAA] or in heterozygous Kir6.2
þ/  or SUR1
þ/  mice)
causes a persistent hyperinsulinism, whereas complete loss
(e.g., in KATP KO mice) may transiently cause hypersecretion,
but this is followed by a secretory deﬁcit and reduced glucose
tolerance (Figure 7C) [14,42].
We suggest that this model may be generalizable to
hyperexcitability resulting from any other mechanism, such
as loss of other K
þ conductances, or gain of excitatory
current. However, it is important to note that the model is
developed solely from experiments with genetic manipula-
tion of KATP channel subunits, and requires veriﬁcation by
direct manipulation of excitability in genetically normal
animals. In the present study we have successfully performed
just such an experiment by utilizing slow-release implanted
drug pellets. This approach allowed us to pharmacologically
block KATP channels over a prolonged period in a tractable in
vivo model. The dramatic consequence is that although blood
glucose levels are initially lowered and glucose tolerance is
Figure 6. Impaired Glucose-Dependence of Insulin Secretion in Fresh
Isolated, but Not in 24-h Incubated Islets from Mice Chronically Treated
with Glibenclamide
(A) Insulin content from glibenclamide-pelleted mice.
(B and C) Glucose-sensitive insulin secretion from freshly isolated islets
(B) and from islets incubated in 5.6 mM glucose for 24 h (C). Insulin
release and content was measured by radioimmunoassay. Each group
contained ten mice, and samples were assayed in triplicate. Significant
differences between glibenclamide-implanted and control are indicated
for each assay condition by asterisk.
There were no significant differences in (A).
doi:10.1371/journal.pmed.0050206.g006
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crosses over to hyperglycemia and glucose intolerance that is
strikingly similar to the adult phenotype of KATP KO mice for
all except the very lowest-dose pellets. Earlier studies of
‘‘long-term’’ treatment of animals with sulfonylureas have
generally not gone beyond a few days [46], presumably due to
the practical difﬁculties of injection regimens. Importantly,
young mice injected daily with glibenclamide showed a
degranulation effect in their b-cells, which might explain
the reduced secretory capacity, although this effect was
apparently not present in older mice [47]. Increased basal
insulin secretion but reduced glucose- and glibenclamide-
stimulated insulin secretion have been seen from isolated
islets exposed in vitro to glibenclamide for 24 h [48,49], due
Figure 7. Morphological and Physiological Response to Chronic Hyperexcitability, and Proposed ‘‘Inverse U’’ Model Response for Enhanced b-Cell
Excitability
(A) Hematoxylin-eosin staining (left), glucagon (middle), and insulin (right) immunostaining of pancreatic paraffin sections from WT control and
glibenclamide-implanted mice.
(B) Insulin (green) and TUNEL (red) staining of pancreatic sections from control and glibenclamide-pelleted mice. Left images show images from
untreated sections; right images show islets from paraffin sections treated with recombinant DNAase I (TUNEL-positive controls).
(C) Proposed ‘‘Inverse U’’ model response for enhanced b-cell excitability: normal islets (white circle) secrete normally, but following a high-fat diet
(HFD; grey dashed arrow) progress to insulin hypersecretion. Both Kir6.2[AAA] and heterozygous Kir6.2- and SUR1-KO mice (50%–70% decreased KATP
activity with increased excitability) hypersecrete (grey circles, solid line) and are positioned on the ‘‘ascending limb’’ of the curve [13,14,43]. HFD causes
further enhancement of excitability, beyond the threshold driving those islets ‘‘over the top’’ (dashed) to an undersecretory phenotype. Conversely,
Kir6.2- and SUR1-KO islets (zero KATP channel activity), which have maximally enhanced excitability, hypersecrete as neonates (grey circle on solid line),
but rapidly progress to an undersecretory phenotype (black circle on solid line), and are positioned on the ‘‘descending limb’’ [10–12]. Glibenclamide-
treated WT mice rapidly progress from normal insulin secretion to undersecretion (white circle on ‘‘ascending limb’’ is converted to black circle on
‘‘descending limb’’). This phenotype can be completely reversed when hyperexcitability is removed (small black dashed line). Finally, mice expressing
mutant b-cell KATP channels with enhanced activity (Kir6.2[DN30]) [41] have a severely undersecreting phenotype, extending the ascending limb
beyond the position of normal animals.
doi:10.1371/journal.pmed.0050206.g007
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content [49]. Similarly, chronic exposure of rat pancreatic
islets to sulfonylureas caused reversible impairment of
glucose- and sulfonylurea-induced insulin release [50–52].
While short-term (24 h) exposure of insulinoma cell lines to
SUs induced an increase in GLUT2 and GK mRNA, long-term
(48–72 h) exposure induced a marked reduction of these
glucose mobilizers [53], coupled with a reversible reduction in
insulin content with no changes in Kir6.2 or SUR1 transcripts
(72–144 h) [39]. Here we demonstrate that intact mice treated
with chronic glibenclamide show no signiﬁcant changes in
islet insulin content, although a very mild reduction in insulin
content was found in islets from mice implanted with the
highest dose (Figure 6). Instead, our results indicate very
speciﬁcally that chronic glibenclamide treatment in vivo
induces b-cell desensitization (impairment of insulin secre-
tion) rather than inhibition of insulin production [54].
86Rb
þ-
efﬂux experiments on fresh isolated islets from glibencla-
mide-implanted mice demonstrate that substantial inhibition
of KATP activity is present (Figure 5), which predicts hyper-
excitability and elevated [Ca
2þ], as has been seen in KATP KO
animals. This would in turn stimulate insulin secretion, which
suggests that the impairment of secretion is at a stage
downstream of Ca
2þ, presumably at the level of insulin
production or mobilization, or at the level of b-cell mass.
There is a remarkable and rapid recovery of both KATP
activity and normal insulin secretion within 24 h of islet
isolation from these mice, arguing against b-cell apoptosis or
other types of cell death induced by chronic glibenclamide
treatment in vivo, and supported by the immunhistological
analyses in Figure 7A and 7B.
Clearly, recovery of both KATP conductance and secretion
is rapid (within hours of removal of islets from the animal),
and although unassessable, the most reasonable explanation
is that the recovery results simply from the washout of the
drug and reversal of the resultant chronic depolarization.
However, the formal possibility remains that the recovery is
due to loss of other neuronal or hormonal inputs present in
the intact animal. The level of KATP activity in Figure 5,
assessed about 2 h after isolation, is an upper limit estimate,
since some recovery may already have occurred and, in vivo,
the degree of inhibition may be considerably greater. That
this is likely is illustrated in Figure 5: except for the very
lowest dose of implanted glibenclamide pellets, the glucose-
lowering effect of injected glibenclamide, which reﬂects the
degree of KATP inhibition possible, was negligible.
The ‘‘Inverse U’’ Model Is Reversible: Removal of the
Hyperexcitable Stimulus Restores Normal Responsivity
In the genetic models of hyperexcitability, progression
onto the ‘‘descending limb’’ of the ‘‘inverse U’’ response is
permanent; glucose intolerance persists throughout the
lifetime of KATP KO animals, and in reduced KATP animals
when under dietary stress. However, it appears that this
progression is rapidly reversible if excitability is normalized
(as we show here), or if the dietary stress is removed [42]. As
we discuss further below, various studies have suggested that
‘‘resting’’ pancreatic b-cells, by exogenous suppression of
blood glucose, can restore function in diabetic states. This is
the case for high-fat diet–induced glucose intolerance in
Kir6.2
þ/ [AAA] mice [42]. Within 2 wk of restoration of
normal diet, Kir6.2
þ/ [AAA] mice recover secretory capacity
and glycemic control to near normal [42]. Genetic restoration
of excitability has not been attempted in KO mice, but the
present study allows us to begin to assess the lability of this
effect. First, the pellets are designed to release at the
appropriate dose for ;90 d. The hyperglycemia and
hypoinsulinism that develop within a few days of pellet
implantation is maintained for at least 6 wk (42 d, Figures 1
and 4), and we did not routinely monitor animals after this
time. However, we did assess a small number of animals at 95
and 118 d after implantation, i.e., 5 and 28 d after the pellets
should have stopped releasing. By 1 mo, glucose tolerance is
restored (Figures 2F and 3F) and even at only 5 d there is
marked normalization of blood glucose and glucose tolerance
(Figures 2E and 3E). These results strongly demonstrate that
insulin secretory failure in response to loss-of-KATP activity is
reversible, if hyperexcitability is removed.
More dramatically, isolated islets from implanted mice
reveal rapid reversibility at the cellular level. Within a few
hours of removal from the circulating glibenclamide, isolated
islets regain not only essentially normal KATP activity but they
regain essentially normal GSIS too. This means that whatever
underlying mechanism causes the secretory failure, it is fully
and rapidly reversible. Although 5.6 mM glucose is not
particularly high, the ﬁnding that overnight incubation is
sufﬁcient to restore the secretory response to glucose in these
islets may have parallels with the recent ﬁnding that
overnight incubation of SUR1 KO islets in elevated (10 mM)
glucose also restores insulin secretory capacity [55].
Relevance of the Present Findings for Type 2 Diabetes
The present ﬁndings have implications both for the
potential etiology of type 2 diabetes and for pharmacological
intervention. People with type 2 diabetes typically experience
a gradual loss of secretory function. In many patients, SUs
effectively control glycemia for an extended period [33], but
over the long term (months to years) SU therapies often fail
[33,56,57]. Several animal studies [28,58,59] and studies of
isolated islets and cells [37,52] provide evidence that long-
term SU treatment leads to impaired glucose tolerance and
GSIS. The present study shows a markedly impaired secretory
response to chronic glibenclamide that can be rapidly
reversed following removal of the drug in vitro. In the
implanted animals, glibenclamide release is continuous, and
in patients, dosing is pulsatile. Conceivably, pulsatile pre-
sentation may provide islets with unstimulated periods that
allow restoration of secretory capacity and responsivity. This
rationale may suggest that lower-potency, shorter-acting SUs
might be more efﬁcacious therapeutically. In nonobese
people with type 2 diabetes, including those in whom SUs
secondarily fail, there are reports of signiﬁcant restoration of
b-cell secretory activity after a brief period of intensive
insulin therapy [60,61]. This ﬁnding may argue for re-
evaluation of short-acting analogs and give cause to further
consider approaches [62] to reverse loss of secretory response
in patients with type 2 diabetes following long-term SU
treatment, and thereby prolong the use of pharmacothera-
pies and delay the need to switch to insulin.
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Editors’ Summary
Background. Diabetes is an increasingly common chronic disease
characterized by high blood sugar (glucose) levels. In normal people,
blood sugar levels are controlled by the hormone insulin. Insulin is
released by b-cells in the pancreas when blood glucose levels rise after
eating (glucose is produced by the digestion of food). In fasting people,
membrane proteins called ATP-sensitive potassium (KATP) channels keep
the b-cell in a ‘‘hyperpolarized’’ state in which they do not secrete
insulin. After a meal, glucose enters the b-cell where its chemical
breakdown converts ADP into ATP (the molecule that provides the
energy that drives cellular processes). The increased ratio of ATP to ADP
closes the KATP channels, ‘‘depolarizes’’ the b-cells, and allows the entry
of calcium ions, which trigger insulin release. The released insulin then
‘‘instructs’’ insulin-responsive muscle and fat cells to take up glucose
from the bloodstream. In type 2 diabetes, the commonest type of
diabetes, the muscle and fat cells gradually become nonresponsive to
insulin and consequently blood glucose levels rise. Over time, this
hyperglycemia increases the risk of heart attacks, kidney failure, and
other life-threatening complications. On average, people with diabetes
die 5–10 y younger than people without diabetes.
Why Was This Study Done? People with type 2 diabetes are often
initially treated with drugs called sulfonylureas (for example, glibencla-
mide). Sulfonylureas help to reduce blood glucose levels by inhibiting (in
effect, closing) the KATP channels, which enhances insulin secretion.
Unfortunately, after patients have been treated for several years with
sulfonylureas, their b-cells often stop secreting insulin and the patients
then have to inject insulin to control their blood sugar levels. The
mechanism by which chronic sulfonylurea treatment affects b-cell
behavior is poorly understood, which means that it is hard to improve
this antidiabetes treatment. Mice that have been genetically altered so
that they have no KATP channels (KATP knockout mice) also rapidly lose
their ability to secrete insulin, although they secrete unusually large
amounts at birth. This suggests that permanent membrane depolariza-
tion (b-cell hyperexcitability) may cause insulin secretory failure. In this
study, the researchers investigate whether this mechanism might be
responsible for sulfonylurea-induced loss of insulin secretion.
What Did the Researchers Do and Find? The researchers implanted
slowly releasing pellets of glibenclamide into wild-type mice and then
monitored their blood glucose levels and glucose tolerance (the speed of
glucose removal from the blood after a glucose ‘‘meal’’) for up to 128 d;
the pellets released drug for 90 d. The glibenclamide-implanted mice
progressively developed diabetes, lost the ability to secrete insulin in
response to glucose and, after 1 wk of treatment, were as glucose
intolerant as adult KATP knockout mice. Compared to freshly isolated b-
cells from untreated wild-type mice, glucose-stimulated insulin secretion
by b-cells isolated from glibenclamide-treated wild-type mice and from
KATP knockout mice was reduced to a similar degree. However, the
secretory capacity of b-cells isolated from the glibenclamide-treated
wild-type mice was restored to normal within hours of drug washout and
was normal in b-cells isolated from treated mice 1 mo after exhaustion of
the slow-release pellets. Consistent with this result, there was no obvious
b-cell death in the glibenclamide-treated mice.
What Do These Findings Mean? Although findings from animal studies
do not always reflect what happens in people, these findings suggest
that insulin secretion might sometimes fail in people who take
sulfonylureas for a long time, because these drugs cause b-cell
hyperexcitability. The finding that the secretory failure caused by
sulfonylurea treatment is reversible is important because it suggests
that short-acting sulfonylureas might be re-evaluated to see whether
they could delay sulfonylurea-induced failure of the insulin secretory
response by providing the pancreatic b-cells with periods when they are
not depolarized. This finding (and the absence of b-cells death in the
glibenclamide-treated mice) also suggests that there may be a way to
reverse the loss of the insulin secretory response in patients who have
taken sulfonylureas for a long time. Both approaches could help patients
with diabetes delay or even avoid the need for insulin injections.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050206.
  This study is further discussed in a PLoS Medicine Perspective by
Renstrom and colleagues
  The MedlinePlus encyclopedia provides information for patients about
diabetes (in English and Spanish)
  The US National Diabetes Information Clearinghouse provides
information on all aspects of diabetes (in English and Spanish)
  The International Diabetes Federation also provides comprehensive
information about diabetes
  Wikipedia has pages on KATP channels and on sulfonylurea drugs (note:
Wikipedia is a free online encyclopedia that anyone can edit; available in
several languages)
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